Phase II randomized study of doxorubicin, vincristine, and 5-FU versus cyclophosphamide in advanced squamous cell carcinoma of the cervix.
Sixty-one evaluable patients with advanced squamous cell carcinoma of the cervix were treated in a randomized fashion with either doxorubicin, vincristine, and 5-FU in combination (AVF) or with cyclophosphamide (CTX). Of 31 patients treated with AVF, only three (10%) responded (one complete response and two partial responses). Of 30 patients treated with CTX, there were two (7%) with partial responses. Two patients responded to AVF after failing CTX; one patient responded to CTX after failing AVF. Neither of these regimens was predictably useful in our patient population.